The initiation of coverage with a Buy rating and a specific price target of $36 by Truist Securities is likely to positively impact the stock price of Nurix Therapeutics in the short term. Analyst ratings and price targets are significant indicators for investors, and a Buy rating typically suggests confidence in the company's future performance.